Completion of recruitment for KALUMA study by WANECAM-2 Consortium

On 29 May 2025, the West African Network for Clinical Trials of Antimalarial Drugs (WANECAM-2) consortium announced the successful completion of recruitment for the KALUMA study. This marks a significant milestone in their research efforts, with nearly 1,700 patients enrolled in the trial.

The KALUMA study follows the promising results announced in November 2024 of the phase 2b trial of the novel, non-artemisinin drug ganaplacide (also known as KAF156) combined with a new once-daily formulation of lumefantrine in young children (6 months to 2 years old). Given the promising findings, the investigators started an efficacy phase 3 trial in March 2024 using the same formulation as in the phase 2b study in patients weighing ≥ 5 kg and aged ≥ 2 months, suffering from uncomplicated P. falciparum malaria (with or without other Plasmodium spp. co-infection).

Results from the KALUMA study are expected soon.